Printer Friendly

SCIENTIFIC DEVELOPMENTS ADD TO VIRULIZIN KNOWLEDGE BASE

 SCIENTIFIC DEVELOPMENTS ADD TO VIRULIZIN KNOWLEDGE BASE
 TORONTO, Sept. 10 /PRNewswire/ -- IMUTEC Corporation (formerly RML Medical Laboratories Inc.) announced today that recent scientific development programs have significantly increased the base of knowledge about VIRULIZIN(TM), the company's investigational cancer drug currently in Phase II clinical trials in Canada and Mexico.
 Physical, chemical and biochemical characterization of VIRULIZIN and defined in-vitro biological activity have now been established. In addition, on a pilot plant basis, VIRULIZIN is being produced consistently. Bioassays have defined standard international units of VIRULIZIN, while biochemical characterization has revealed a consistent peptide "fingerprint" from batch to batch. Together, these tests demonstrate that the identity, potency and purity of VIRULIZIN are ensured and that the product can be manufactured predictably.
 VIRULIZIN has been found to contain no detectable components of high molecular weight which can cause harmful immunologic reactions. Because VIRULIZIN's biological activity is associated with components of low molecular weight the drug should have a long shelf life.
 Laboratory tests have shown that VIRULIZIN inhibits the growth of mouse hybridoma (cancerous) cells and stimulates the growth of certain normal cells under "stress conditions" associated with disease. Scientific development programs in recent months have also established that VIRULIZIN does not contain or stimulate the production of a number of common cytokines (such as Interleukin-B) which make up other biopharmaceuticals - indicating that these cytokines play no part in VIRULIZIN's action.
 "These developments will strengthen the company's position during negotiations with multinational pharmaceutical companies and in discussions with health regulators and the medical community," President Richard A. Potts said.
 As a result of recommendations by the clinical trial investigators and the company's Medical Advisory Board in March of this year, the latest clinical trials with VIRULIZIN in Mexico have been based on a protocol which calls for substantially increased dosage frequency - an option allowable because VIRULIZIN is non-toxic and causes few side effects. All future trials in Canada, the United States and Europe will also use the more frequent administration schedule.
 IMUTEC is a biotechnology company using a proprietary technology to develop and commercialize naturally derived immunologic pharmaceuticals for use in the treatment of diseases. To date, IMUTEC has applied its technology to produce VIRULIZIN, a potential new drug for the treatment of cancer.
 VIRULIZIN is currently undergoing Phase II clinical trials on the following types of cancer: pancreatic, malignant melanoma, kidney, stomach, and recurrent rectum and colon.
 -0- 9/10/92
 /CONTACT: Dr. Judith A. Burgess, medical director of IMUTEC Corporation, 416-724-1100 or 800-561-9400; Jeffrey Elliott, 416-362-8000, for IMUTEC Corporation/ CO: IMUTEC Corporation ST: Ontario IN: MTC SU:


SM -- NY037 -- 7947 09/10/92 11:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 10, 1992
Words:437
Previous Article:ROCKWELL INTERNATIONAL INTRODUCES WORLD'S FIRST FULLY INTEGRATED CALL PROCESSING SYSTEM
Next Article:CASINO AMERICA FILES AMENDMENT TO REGISTRATION STATEMENT
Topics:


Related Articles
IMUTEC CORPORATION PHASE II STUDY OF VIRULIZIN IN PATIENTS WITH PANCREATIC CANCER RELEASED
IMUTEC REPORTS FIRST QUARTER RESULTS
IMUTEC CORPORATION REPORTS SECOND QUARTER RESULTS
PHASE II CLINICAL TRIAL RESULTS RELEASED - VIRULIZIN PROVIDES BENEFITS TO ADVANCED MALIGNANT MELANOMA PATIENTS
DR. JULES E. HARRIS APPOINTED TO IMUTEC MEDICAL ADVISORY BOARD
IMUTEC PURSUES PROGRAM OF PHASE III CLINICAL TRIALS
VIRULIZIN INCREASES SURVIVAL RATE IN ADVANCED MALIGNANT MELANOMA PATIENTS
Lorus presents Virulizin(R) results at 20th National Medical Meeting of the "Instituto Nacional de Cancerologia" - Company presents Virulizin to...
Lorus Therapeutics' scientific publication expands the potential anticancer applications of Virulizin(R); - Studies published in peer reviewed...
Lorus presents at American Society of Clinical Oncology today.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters